<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1120">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04469179</url>
  </required_header>
  <id_info>
    <org_study_id>SAB-185-102</org_study_id>
    <nct_id>NCT04469179</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19</brief_title>
  <official_title>A Phase 1B, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of SAB-185 in Ambulatory Subjects With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SAb Biotherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomedical Advanced Research and Development Authority</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Joint Program Executive Office (JPEO) Chemical, Biological, Radiological, and Nuclear Defense (CBRND) Enabling Biotechnologies (EB)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SAb Biotherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      : Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute&#xD;
      respiratory syndrome coronavirus 2 (SARS-CoV-2). SAB Biotherapeutics has developed SAB-185,&#xD;
      an Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (transchromosomic [Tc] bovine-derived),&#xD;
      as a potential therapeutic to treat COVID-19. This study will evaluate the safety,&#xD;
      immunogenicity, and pharmacokinetics of SAB-185 in ambulatory participants with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Having Adverse Events</measure>
    <time_frame>29 Days</time_frame>
    <description>Incidence and severity of other adverse events and severe adverse events (SAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Having Transfusion-Related Adverse Events</measure>
    <time_frame>29 Days</time_frame>
    <description>transfusion-related adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Having Adverse Events</measure>
    <time_frame>90 Days</time_frame>
    <description>Incidence and severity of adverse events and SAEs from Screening through Study Day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assesment of the PD of SAB-185 administered intravenously</measure>
    <time_frame>90 Days</time_frame>
    <description>Measurement of SARS CoV-2 neutralizing (PRNT80) antibody titers from screening through Study Day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response elicited by SAB-185</measure>
    <time_frame>90 Days</time_frame>
    <description>Measurement of Rheumatoid factor through day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of subject anti-SAB-185 antibodies elicited by SAB-185</measure>
    <time_frame>90 Days</time_frame>
    <description>Measurement of anti-SAB-185 antibodies through screening day 90</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens</measure>
    <time_frame>29 Days</time_frame>
    <description>Incidence of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of SARS-CoV-2 in oropharyngeal (OP) or nasopharyngeal (NP) swab specimens</measure>
    <time_frame>29 Days</time_frame>
    <description>Level of SARS-CoV-2 in swab specimens as measured by quantitative RT-PCR through Study Day 29</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">21</enrollment>
  <condition>COVID-19</condition>
  <condition>SARS-CoV2</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10mg/kg SAB-185 in normal (0.9%) saline; concentration 4mg/mL (0.4%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50mg/kg SAB-185 in normal (0.9%) saline; concentration 20mg/mL (2%)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SAB-185</intervention_name>
    <description>SAB-185 is a purified human immunoglobulin G (hIgG) designed to specifically bind to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) viruses. SAB-185 is purified from the plasma of immunized Tc bovines that were immunized initially (vaccinations 1 and 2) with a plasmid DNA (pDNA) vaccine that expresses wild-type SARS-CoV-2 spike protein, followed by additional immunizations (vaccinations 3 and beyond) with a recombinant spike protein from SARS-CoV-2 produced in insect cells. The purified hIgG is a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Anti-SARS-CoV-2 Human Immunoglobulin Intravenous (Tc bovine-derived)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria for inclusion:&#xD;
&#xD;
          1. 18-60 years of age&#xD;
&#xD;
          2. Positive for presence of SARS-CoV-2 on NP or OP swab by FDA-authorized RT-PCR test&#xD;
             within seven days prior to infusion&#xD;
&#xD;
          3. At least one current symptom of COVID-19, onset within seven days prior to infusion:&#xD;
&#xD;
               -  Fever or chills&#xD;
&#xD;
               -  Cough&#xD;
&#xD;
               -  Shortness of breath or difficulty breathing&#xD;
&#xD;
               -  Fatigue&#xD;
&#xD;
               -  Muscle or body aches&#xD;
&#xD;
               -  Headache&#xD;
&#xD;
               -  New loss of taste or smell&#xD;
&#xD;
               -  Sore throat&#xD;
&#xD;
               -  Congestion or runny nose&#xD;
&#xD;
               -  Nausea or vomiting&#xD;
&#xD;
               -  Diarrhea&#xD;
&#xD;
          4. Able to understand the study and comply with all study procedures&#xD;
&#xD;
          5. Agrees not to participate in any other trial of an investigational product during the&#xD;
             study period&#xD;
&#xD;
          6. Willing and able to provide written informed consent prior to the start of any study&#xD;
             related activities&#xD;
&#xD;
          7. If female, meets at least one of the following reproductive risk criteria&#xD;
&#xD;
               -  Post-menopausal for at least 12 months&#xD;
&#xD;
               -  Use of one or more of the following highly effective contraceptive methods for at&#xD;
                  least 90 days following the last dose of study product: combined estrogen and&#xD;
                  progestogen containing or progestogen-only hormonal contraception, intrauterine&#xD;
                  device (IUD), intrauterine hormone-releasing system, surgical bilateral tubal&#xD;
                  occlusion&#xD;
&#xD;
               -  Vasectomized sole sexual partner who has received medical assessment of the&#xD;
                  surgical success&#xD;
&#xD;
          8. Male and female subjects agree to sexual abstinence (refraining from heterosexual&#xD;
             intercourse for at least 90 days following the last dose of study product) if not&#xD;
             using birth control or condoms for males.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the criteria of severe or higher COVID-19 will be excluded from&#xD;
        the study:&#xD;
&#xD;
          -  Dyspnea at rest&#xD;
&#xD;
          -  Respiratory rate &gt; 30 breaths per minute&#xD;
&#xD;
          -  SpO2 ≤ 93% on room air&#xD;
&#xD;
          -  Heart rate ≥ 125 beats per minute&#xD;
&#xD;
          -  Respiratory distress or respiratory failure.&#xD;
&#xD;
          -  Evidence of critical illness&#xD;
&#xD;
               1. Female subjects with positive pregnancy test, breastfeeding, or planning to&#xD;
                  become pregnant/breastfeed during the study period.&#xD;
&#xD;
               2. Hospitalization or need for hospitalization for any cause&#xD;
&#xD;
               3. Treatment or participation in another clinical trial of any other investigational&#xD;
                  agent within 30 days prior to enrollment.&#xD;
&#xD;
               4. Use of other drugs that, in the opinion of the investigator, could complicate&#xD;
                  analysis of SAB-185.&#xD;
&#xD;
               5. Subjects with the following risk factors:&#xD;
&#xD;
          -  Compromised immune system including confirmed diagnosis of current cancer under&#xD;
             treatment, inherited deficiencies of the immune system, immune suppressing medication,&#xD;
             or other conditions causing leukopenia or neutropenia&#xD;
&#xD;
          -  Known autoimmune condition requiring therapy more intensive than intermittent&#xD;
             non-steroidal anti-inflammatories in the prior 6 months (for example: rheumatoid&#xD;
             arthritis, lupus, inflammatory bowel disease)&#xD;
&#xD;
          -  Chronic respiratory disease including COPD, emphysema, cystic fibrosis, pulmonary&#xD;
             hypertension, or other chronic condition that requires the routine use of supplemental&#xD;
             oxygen&#xD;
&#xD;
          -  Chronic asthma requiring the use of oral steroids or hospitalization in the last six&#xD;
             months&#xD;
&#xD;
          -  Renal failure or renal insufficiency requiring dialysis&#xD;
&#xD;
          -  Congestive heart failure or significant atherosclerotic disease (coronary artery&#xD;
             disease or peripheral vascular disease) 6. Receipt of pooled immunoglobulin or plasma&#xD;
             in past 30 days 7. Any other underlying medical (cardiac, liver, renal, neurological,&#xD;
             respiratory) or psychiatric condition that in the view of the investigator would&#xD;
             preclude use of SAB-185 8. Known IgA deficiency or previous allergic reaction to&#xD;
             intravenous immunoglobin (IVIG)/subcutaneous immunoglobin (SCIG) 9. Positive for&#xD;
             hepatitis B virus surface antigen, hepatitis C virus antibody, or HIV antibody by&#xD;
             medical history 10. History of allergy, anaphylaxis, or severe reaction to beef&#xD;
             products (including milk and gelatin).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Hoover, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ICON GPHS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Moronke Iyoha</last_name>
    <phone>1.800.431.9640</phone>
    <phone_ext>x269</phone_ext>
    <email>MIyoha@icongphs.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Quantum Clinical Trials</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Herman</last_name>
      <phone>954-350-0767</phone>
      <email>jack@qctrials.com</email>
    </contact>
    <investigator>
      <last_name>Gene Neytman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LuAnn Larson</last_name>
      <phone>402-559-8555</phone>
      <email>llarson@unmc.edu</email>
    </contact>
    <investigator>
      <last_name>Andre Kalil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanford Health</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Pohlson</last_name>
      <phone>605-312-6132</phone>
      <email>mailto:kathryn.pohlson@sanfordhealth.org</email>
    </contact>
    <investigator>
      <last_name>Susan Hoover, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 8, 2020</study_first_submitted>
  <study_first_submitted_qc>July 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2020</study_first_posted>
  <last_update_submitted>September 4, 2020</last_update_submitted>
  <last_update_submitted_qc>September 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in the published article, after deidentification (test, tables, figures, and appendices)</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Starting 6 months after publication and ending 36 months following article publication</ipd_time_frame>
    <ipd_access_criteria>Anyone who wishes to access the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

